Respiri (ASX:RSH) - Ambassador, Michael Clarke
Ambassador, Michael Clarke
Source: Respiri
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Respiri (RSH) has signed a merchant services agreement with buy now, pay later giant Zip Co’s (Z1P) subsidiary, Zip Money Payments
  • As more businesses in Australia’s pharmacy industry are providing buy now, pay later services, Respiri thought it was time to do the same
  • The e-Health company considers the latest agreement important in providing flexible payments options for people to access its wheezo device
  • This agreement follows an international sales agreement with Cipla Australia
  • Company shares are up 13.8 per cent and are trading for 16.5 cents each

Respiri (RSH) has signed a merchant services agreement with buy now, pay later giant Zip Co’s (Z1P) subsidiary, Zip Money Payments.

Respiri is an e-Health software-as-a-solution (SaaS) company supporting respiratory health management.

Its world-first technology detects wheezing, which is a typical symptom of asthma, chronic obstructive pulmonary disease (COPD) and respiratory disease to accurately measure airway limitations.

This agreement follows a recently signed exclusive international sales agreement with Cipla Australia.

Under the agreement, Cipla will order at least 2000 wheezo devices from Respiri.

“The recently announced pharmacy sales and marketing, distribution and logistics agreement with Cipla Australia is expected to significantly increase both pharmacy awareness and patient access to our proprietary wheezo device alongside our training and education initiatives with the Pharmacy Guild of Australia,” CEO Marjan Mikel said.

Respiri considers the latest agreement a way to provide people, no matter their financial situation, with its wheezo device.

“Our agreement with ZIP provides asthmatic patients seeking access to our platform additional financial flexibility when making these important healthcare decisions relating to improvements in the management of their disease,” Marjan stated.

Buy now, pay later services are on the rise in the Australian pharmacy segment; around one in 10 of the general population now utilise flexible payment options.

Company shares are up 13.8 per cent and are trading for 16.5 cents each at 1:12 pm AEST.

rsh by the numbers
More From The Market Online

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

TruScreen Group advances Bangladesh opportunity to drive Indian subcontinent expansion

TruScreen Group has completed a successful product presentation and training visit to Dhaka, Bangladesh as part…

Argent Biopharma executes global licence for non-core Cannabis genetics

Argent BioPharma has entered into a worldwide licensing agreement with TPI for the commercial development of…